ERC-2018-PoC
ERC-2018-PoC
Programme: H2020
160 projects · €23,921,092 total EU contribution (project-level) · 125 participating organizations · 20 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€23,921,092
Countries active
Participant organizations by country (headquarters in CORDIS).
- Italy (17)
- UK (17)
- Spain (16)
- Germany (14)
- Netherlands (13)
- France (10)
- AT (6)
- CH (6)
- FI (4)
- IL (4)
- BE (3)
- IE (3)
- PT (3)
- SE (2)
- SK (2)
- BG (1)
- CY (1)
- DK (1)
- HR (1)
- NO (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- WEIZMANN8 projects · IL
- UOXF7 projects · UK
- CNRS5 projects · FR
- TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY5 projects · IL
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE5 projects · UK
- CNRS INNOVATION4 projects · FR
- IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE4 projects · UK
- POLIMI4 projects · IT
- IIT3 projects · IT
- IRB BARCELONA - CERCA3 projects · ES
- IBM3 projects · CH
- UNIVERSITY COLLEGE LONDON3 projects · UK
Projects
Page 12 of 16
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Innovative therapeutic tools to ameliorate chemotherapy-induced cardiotoxicity p38_InTh · 825763 | H2020 | €149,937 | €149,938 | Details |
NEW METHOD TO ACTIVATE STREPTOMYCES SECONDARY METABOLISM CRYPTIC PATHWAYS StrepCryptPath · 835857 | H2020 | €150,000 | €150,000 | Details |
Cavity-enhanced optical microscope COM · 838894 | H2020 | €149,875 | €149,875 | Details |
Psychiatric Disorders: ATX-inhibiting drugs as a new therapeutic option: Proof-of-Concept PsychAID · 811385 | H2020 | €149,375 | €149,375 | Details |
User-Friendly Software For the Quantitative Analysis of Textual Data QUANTEDA · 812960 | H2020 | €150,000 | €150,000 | Details |
Short, weakly interacting RNA ligands for the development of high-concentration monoclonal antibody therapeutics SWIRL · 812766 | H2020 | €150,000 | €150,000 | Details |
Development of new therapy for rare motor neuron diseases Treat-HSP · 825713 | H2020 | €150,000 | €150,000 | Details |
A new crop protection strategy by chemical priming of the plant immune system ChemPrime · 824985 | H2020 | €148,318 | €148,318 | Details |
CellProbe: Microfluidic probe for simultaneous tagging and extraction of single cells CellProbe · 842790 | H2020 | €150,000 | €150,000 | Details |
VIrTual BrAin PErfusion: Assessing cerebrovascular function by High Performance Computing from 3D brain vessel network data for vascular-targeted drug development in neurodegenerative diseases. VITAE · 825829 | H2020 | €149,738 | €149,738 | Details |